Abstract
Diabetes mellitus (DM) is a metabolic disorder which is characterized by inappropriate hyperglycemia. It is becoming an epidemic disease in developing countries. Diabetic patients are frequently afflicted with a vascular dysfunction and wound healing defect. In spite of intense investigations, over the past 2-3 decades, optimal treatment options and related mechanisms are still unclear. MicroRNAs (miRNAs) are small noncoding RNAs considered as regulators of a vast number of biological processes including endothelial cell function controlling molecular signaling pathways in diabetic pathogenesis. Down regulation of microRNA-126 (miR-126) which may regulate angiogenesis and vascular integrity plays a significant role in the pathogenesis and complications of DM. This paper discusses the potential application of miR-126 as a novel therapeutic agent capable of reducing diabetic vascular complications in different types of DM based on the up-to-date reports.
Keywords: Angiogenesis, diabetes mellitus, miR-126, vascular complications, microRNAs, hyperglycemia.
Current Pharmaceutical Design
Title:miR-126 as a Therapeutic Agent for Diabetes Mellitus
Volume: 23 Issue: 22
Author(s): Elham Pishavar and Javad Behravan*
Affiliation:
- Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Angiogenesis, diabetes mellitus, miR-126, vascular complications, microRNAs, hyperglycemia.
Abstract: Diabetes mellitus (DM) is a metabolic disorder which is characterized by inappropriate hyperglycemia. It is becoming an epidemic disease in developing countries. Diabetic patients are frequently afflicted with a vascular dysfunction and wound healing defect. In spite of intense investigations, over the past 2-3 decades, optimal treatment options and related mechanisms are still unclear. MicroRNAs (miRNAs) are small noncoding RNAs considered as regulators of a vast number of biological processes including endothelial cell function controlling molecular signaling pathways in diabetic pathogenesis. Down regulation of microRNA-126 (miR-126) which may regulate angiogenesis and vascular integrity plays a significant role in the pathogenesis and complications of DM. This paper discusses the potential application of miR-126 as a novel therapeutic agent capable of reducing diabetic vascular complications in different types of DM based on the up-to-date reports.
Export Options
About this article
Cite this article as:
Pishavar Elham and Behravan Javad *, miR-126 as a Therapeutic Agent for Diabetes Mellitus, Current Pharmaceutical Design 2017; 23 (22) . https://dx.doi.org/10.2174/1381612823666170424120121
DOI https://dx.doi.org/10.2174/1381612823666170424120121 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Metabolism and Nutrient Partitioning Strategies
Current Drug Targets - CNS & Neurological Disorders Molecular Hydrogen: New Antioxidant and Anti-inflammatory Therapy for Rheumatoid Arthritis and Related Diseases
Current Pharmaceutical Design Rapid and Simple Profiling of Lipoproteins by Polyacrylamide-Gel Disc Electrophoresis to Determine the Heterogeneity of Low-Density Lipoproteins (LDLs) Including Small, Dense LDL
Recent Patents on Cardiovascular Drug Discovery Consequences of Type 1 and 2 Diabetes Mellitus on the Cardiovascular Regulation During Exercise: A Brief Review
Current Diabetes Reviews Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Amino Thiols, Detoxification and Oxidative Stress in Pre-Eclampsia and Other Disorders of Pregnancy
Current Pharmaceutical Design Growth Hormone Secretagogue (Ghrelin-) Receptors - A Complex Drug Target for the Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Systemic Administration of Fluoro-Gold for the Histological Assessment of Vascular Structure, Integrity and Damage
Current Neurovascular Research PUFA Supplements and Type 2 Diabetes in the Elderly
Current Pharmaceutical Design Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine Human Amylin: From Pathology to Physiology and Pharmacology
Current Protein & Peptide Science Estrogens Acting as Cardiovascular Agents: Direct Vascular Actions
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?
Current Alzheimer Research Polymeric Nanoparticles for Ophthalmic Drug Delivery: An Update on Research and Patenting Activity
Recent Patents on Nanomedicine The Immune System and the Brain: Crosstalk with a Broad Impact From Host Defense to Cognition
Current Neurovascular Research Nanotechnology in Insulin Delivery for Management of Diabetes
Pharmaceutical Nanotechnology